Novavax to Participate in Fireside Chat at Devex @ UNGA 76
Get Alerts NVAX Hot Sheet
Join SI Premium – FREE
GAITHERSBURG, Md., Sept. 20, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing and commercializing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer, will be interviewed at Devex @ UNGA 76 on September 21 at 8:50 a.m. The event is hosted by the media outlet Devex and is taking place September 21-23 via livestream as part of its coverage of the 76th meeting of the United Nations General Assembly (UNGA 76). Novavax' COVID-19 vaccine candidate, NVX-CoV2373, will be a topic of discussion along with fostering global vaccine access.
Interview details are as follows:
Date: | Tuesday, September 21, 2021 |
Time: | 8:50 - 9:05 a.m. |
Location: | |
Title: | Fireside chat: A status report on the COVID-19 vaccine rollout |
Novavax panelist: | John J. Trizzino, Executive Vice President, Chief Commercial Officer and Chief Business Officer |
Moderator: | Jenny Lei Ravelo, Senior Reporter, Devex |
For more information or to register for the fireside chat, visit:https://pages.devex.com/devex-at-unga-76.html
About NovavaxNovavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases. The company's proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles designed to address urgent global health needs. Novavax is conducting late-stage clinical trials for NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults and will be advanced for regulatory submission. Both vaccine candidates incorporate Novavax' proprietary saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Contacts: InvestorsNovavax, Inc.Erika Schultz | 240-268-2022[email protected]
Solebury TroutAlexandra Roy | 617-221-9197[email protected]
MediaAlison Chartan | 240-720-7804Laura Keenan | 202-709-7521[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-fireside-chat-at-devex--unga-76-301380800.html
SOURCE Novavax, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Asphalt Expert Robert Stewart Explains Asphalt Driveway Installation Preparation in HelloNation
- Small Business, Big Trust: How Local Locksmiths Compete With National Call Centers
- pixelgrinder Announces Second Full-Length Album “White Mask” for September 25 Release
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share